Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens.
Adolescent
Adult
Aged
Aged, 80 and over
Albendazole
/ therapeutic use
Anthelmintics
/ therapeutic use
Antibodies, Protozoan
/ blood
Antigens, Protozoan
/ immunology
Case-Control Studies
Child
Child, Preschool
Cross-Sectional Studies
Female
Hookworm Infections
/ drug therapy
Humans
Immunoglobulin G
/ blood
Longitudinal Studies
Malaria Vaccines
/ genetics
Malaria, Falciparum
/ immunology
Male
Middle Aged
Parasitemia
/ parasitology
Protozoan Proteins
/ immunology
Young Adult
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
08 Apr 2021
08 Apr 2021
Historique:
received:
13
11
2020
accepted:
30
03
2021
entrez:
9
4
2021
pubmed:
10
4
2021
medline:
4
5
2021
Statut:
epublish
Résumé
Malaria and helminths diseases are co-endemic in most parts of sub-Saharan Africa. Immune responses from each of these pathogens interact, and these interactions may have implications on vaccines. The GMZ2 malaria vaccine candidate is a fusion protein of Plasmodium falciparum merozoite surface protein 3 (MSP3) and glutamate rich protein (GLURP R0). GMZ2 has recently showed modest efficacy in a phase IIb multicenter trial. Here, we assessed the effect of hookworm (Necator americanus) infection and anthelmintic treatment on naturally acquired antibody responses against GMZ2 and constituent antigens. This longitudinal cross-sectional study was conducted in the Kintampo North Municipality of Ghana. Blood and stool samples were taken from 158 individuals (4-88 years old) infected with either P. falciparum alone (n = 59) or both hookworm and P. falciparum (n = 63) and uninfected endemic controls (n = 36). Stool hookworm infection was detected by the Kato-Katz method and PCR. Malaria parasitaemia was detected by RDT, light microscopy and P. falciparum-specific 18S rRNA gene PCR. Serum samples were obtained prior to hookworm treatment with a single dose of albendazole (400 mg) and 3 weeks (21 days) after treatment. Levels of IgG1, IgG3 and IgM against GMZ2, MSP3 and GLURP R0 were measured by ELISA and compared among the groups, before and after treatment. Participants with P. falciparum and hookworm co-infection had significantly higher IgG3 levels to GMZ2 than those with only P. falciparum infection and negative control (p < 0.05) at baseline. Treatment with albendazole led to a significant reduction in IgG3 levels against both GMZ2 and GLURP R0. Similarly, IgM and IgG1 levels against MSP3 also decreased following deworming treatment. Individuals with co-infection had higher antibody responses to GMZ2 antigen. Treatment of hookworm/malaria co-infection resulted in a reduction in antibody responses against GMZ2 and constituent antigens after albendazole treatment. Thus, hookworm infection and treatment could have a potential implication on malaria vaccine efficacy.
Sections du résumé
BACKGROUND
BACKGROUND
Malaria and helminths diseases are co-endemic in most parts of sub-Saharan Africa. Immune responses from each of these pathogens interact, and these interactions may have implications on vaccines. The GMZ2 malaria vaccine candidate is a fusion protein of Plasmodium falciparum merozoite surface protein 3 (MSP3) and glutamate rich protein (GLURP R0). GMZ2 has recently showed modest efficacy in a phase IIb multicenter trial. Here, we assessed the effect of hookworm (Necator americanus) infection and anthelmintic treatment on naturally acquired antibody responses against GMZ2 and constituent antigens.
METHODS
METHODS
This longitudinal cross-sectional study was conducted in the Kintampo North Municipality of Ghana. Blood and stool samples were taken from 158 individuals (4-88 years old) infected with either P. falciparum alone (n = 59) or both hookworm and P. falciparum (n = 63) and uninfected endemic controls (n = 36). Stool hookworm infection was detected by the Kato-Katz method and PCR. Malaria parasitaemia was detected by RDT, light microscopy and P. falciparum-specific 18S rRNA gene PCR. Serum samples were obtained prior to hookworm treatment with a single dose of albendazole (400 mg) and 3 weeks (21 days) after treatment. Levels of IgG1, IgG3 and IgM against GMZ2, MSP3 and GLURP R0 were measured by ELISA and compared among the groups, before and after treatment.
RESULTS
RESULTS
Participants with P. falciparum and hookworm co-infection had significantly higher IgG3 levels to GMZ2 than those with only P. falciparum infection and negative control (p < 0.05) at baseline. Treatment with albendazole led to a significant reduction in IgG3 levels against both GMZ2 and GLURP R0. Similarly, IgM and IgG1 levels against MSP3 also decreased following deworming treatment.
CONCLUSION
CONCLUSIONS
Individuals with co-infection had higher antibody responses to GMZ2 antigen. Treatment of hookworm/malaria co-infection resulted in a reduction in antibody responses against GMZ2 and constituent antigens after albendazole treatment. Thus, hookworm infection and treatment could have a potential implication on malaria vaccine efficacy.
Identifiants
pubmed: 33832450
doi: 10.1186/s12879-021-06027-5
pii: 10.1186/s12879-021-06027-5
pmc: PMC8028774
doi:
Substances chimiques
Anthelmintics
0
Antibodies, Protozoan
0
Antigens, Protozoan
0
GMZ2 vaccine
0
Immunoglobulin G
0
Malaria Vaccines
0
Protozoan Proteins
0
merozoite surface protein 3, Plasmodium
0
glutamate-rich protein, Plasmodium
145112-81-8
Albendazole
F4216019LN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
332Références
Parasite Immunol. 2000 Jul;22(7):341-8
pubmed: 10886718
J Infect Dis. 1998 Jul;178(1):289-93
pubmed: 9652458
PLoS Negl Trop Dis. 2010 Nov 09;4(11):e882
pubmed: 21085468
Med J Aust. 1991 Feb 18;154(4):284-9
pubmed: 1994206
Vaccine. 2000 Sep 15;19(2-3):204-12
pubmed: 10930674
Am J Trop Med Hyg. 1991 Sep;45(3):297-308
pubmed: 1928564
Malar J. 2012 Feb 15;11:46
pubmed: 22335967
Infect Immun. 1992 Apr;60(4):1473-81
pubmed: 1548071
Malar J. 2008 Jul 29;7:142
pubmed: 18664257
Clin Diagn Lab Immunol. 1995 Jan;2(1):30-4
pubmed: 7719909
Infect Immun. 2005 Dec;73(12):8017-26
pubmed: 16299295
Trans R Soc Trop Med Hyg. 1988;82(4):532-7
pubmed: 2475928
Vaccine. 2016 Aug 31;34(38):4536-4542
pubmed: 27477844
Vaccine. 2009 Nov 16;27(49):6862-8
pubmed: 19755144
Vaccine. 2010 Sep 24;28(41):6698-703
pubmed: 20696154
BMC Infect Dis. 2008 Nov 17;8:158
pubmed: 19014683
Clin Microbiol Rev. 2001 Oct;14(4):689-703, table of contents
pubmed: 11585781
Parasite Immunol. 2011 Feb;33(2):124-31
pubmed: 21226725
Trends Immunol. 2003 Jan;24(1):30-5
pubmed: 12495722
Nature. 1993 Oct 28;365(6449):797-805
pubmed: 8413664
Infect Immun. 2004 Nov;72(11):6492-502
pubmed: 15501780
Malar J. 2017 Apr 26;16(1):176
pubmed: 28446190
Vaccine. 2012 Dec 14;30(52):7621-4
pubmed: 23085365
Trans R Soc Trop Med Hyg. 1971;65(2):125-35
pubmed: 4934028
Mem Inst Oswaldo Cruz. 2007 Jun;102(3):405-9
pubmed: 17568947
Infect Immun. 2006 Jan;74(1):257-64
pubmed: 16368979
Malar J. 2016 Feb 27;15:123
pubmed: 26921176
N Engl J Med. 2004 Aug 19;351(8):799-807
pubmed: 15317893
Parasitol Today. 1995 Mar;11(3):105-11
pubmed: 15275362
PLoS One. 2019 Sep 12;14(9):e0222382
pubmed: 31513658
Cytokine X. 2019 Oct 04;1(4):100014
pubmed: 33604551